Document is current
Any future updates will be listed below
-
Authors
Sun, Xiaoxiao https://orcid.org/0000-0002-9689-9385
Wu, Lani F.
Altschuler, Steven J. https://orcid.org/0000-0001-9142-0796
Hata, Aaron N. https://orcid.org/0000-0002-6127-318X
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (R01 CA249291, P50 CA265826, R01 CA134832)
Ludwig Center at Harvard Break Through Cancer foundation
Mark Foundation for Cancer Research
- License Information
-
More Information
Article History
Received: 13 September 2023
Accepted: 26 July 2024
First Online: 17 September 2024
Competing interests
: A.N.H. has received grants and/or research support from Amgen, BridgeBio, Bristol Myers Squibb, C4 Therapeutics, Eli Lilly, Novartis, Nuvalent, Pfizer and Scorpion Therapeutics and has served as a compensated consultant for Amgen, Engine Biosciences, Nuvalent, Oncovalent, Pfizer, TigaTx and Tolremo Therapeutics. X.S., L.F.W. and S.J.A. declare no competing interests.
